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Abstract 
Cancer is the second leading cause of human mortality in the United States, with the 
standard treatment options being surgery, cytotoxic chemotherapy, and radiation therapy.  
Recently, there has been strong emphasis in developing targeted small molecule therapies 
which has led to the development of numerous anticancer drugs.  However, many of the 
current cancer chemotherapeutic options are burdened with toxicity and treatment 
resistance and hence novel therapies with reduced side effects are urgently needed.  In the 
current work, a structurally diverse library of Baylis-Hillman reaction derived 2-
(alkoxycarbonyl)-allyl esters have been synthesized, evaluated for their in vitro cell 
proliferation inhibition properties, in vitro cellular and molecular mechanisms of action, 
in vivo systemic toxicity study in CD-1 mice, and in vivo anticancer efficacy study in a 
triple negative breast cancer MDA-MB-231 xenograft model in NOD SCID mice.  
Several of the synthesized compounds exhibit promising in vitro anticancer properties. 
Further, the lead candidate compound is well tolerated in healthy mice as indicated by 
normal body weight changes, and exhibits similar if not slightly better tumor growth 
inhibition properties than clinically available cancer drug doxorubicin. 
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Introduction 
 Cancer is the second leading cause of human mortality behind heart disease in the 
United States.
1
 In fact, it is estimated that in coming years, cancer will become the 
number one cause of death overtaking heart diseases.  According to the 2017 American 
Cancer Society statistics, ~1.7 million new cases of cancer have been reported with 
around 600,000 of these cases resulting in mortality this year.  Across both genders lung 
cancer is the highest in terms of incidence followed by prostate and breast cancer 
respectively and colorectal cancer being the third highest among both.
1
 The standard 
treatment options for cancer involve surgery, cytotoxic chemotherapy and radiation 
therapy.  Recently, there has been a strong emphasis on developing targeted therapies 
including small molecules, monoclonal antibodies, and immuno-therapeutics to deal with 
aggressive solid tumors and improve the overall therapeutic outcome.
2-23
 Classic 
chemotherapy involves treating the patients with cytotoxic agents that target cellular 
DNA, tubulin/microtubules, and antimetabolites.  DNA is a critical cellular component 
with well-defined primary, secondary, and tertiary structures. The genetic information 
encoded in DNA is critical for cell survival and proliferation. Since cancer cells are 
highly proliferative, they need heightened levels of DNA replication, transcription, and 
translation.  Hence, targeting DNA is an attractive choice for anticancer therapy.
24-31
 The 
presence of nucleophilic nitrogen atoms in DNA (i.e., N7-guanidine) also makes it an 
ideal target for designing electrophilic alkylators.  Drug molecules that target DNA can 
be subdivided into DNA alkylators (crosslinkers), DNA topoisomerase inhibitors, DNA-
double and single strand breakers and DNA code reading agents (Figure 1.1). 
32
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Figure 1.1: Different reactive modes of DNA-interaction with DNA-targeting drugs. 
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1A.Classical Alkylating Agents 
Classical alkylating agents introduce alkyl groups onto the nucleophilic DNA.  
Some of the clinically used examples are listed in (Figure 1.2).  
 
Figure 1.2: Examples of nitrogen mustard based DNA alkylating agents. 
The mechanism of action of nitrogen mustards involves conversion of 
chloroethylamine group in to a reactive cyclic aziridinium intermediate which acts as an 
electrophile for interaction with nucleophilic DNA in covalent fashion.  The presence of a 
second chloroethyl group leads to covalent interlinkage of two strands of DNA (Figure 
1.3).  The nucleophilic N7 nitrogen atom of guanine (G) reacts with the aziridinium to 
form G-G linkages resulting in DNA damage leading to cellular apoptosis.
33-36
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Figure 1.3: General mechanism of action of nitrogen mustard based DNA alkylating 
agents. 
A second class of classical alkylating agents includes N-nitrosoureas, which 
similarly add an alkyl group to nucleophilic N7 of guanine, but differ in mechanism 
(Figure 1.4). For example, N-nitrosourea in carmustine undergoes extensive metabolic 
degradation to generate the reactive chloroethyl cation intermediate and 
chloroethylisocyanate. Chloroethyl cation causes crosslinks in DNA and the isocyanate 
intermediate carbamoylates protein components both resulting in cell death pathways 
(Figure 1.5).
37-39
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Figure 1.4: Examples of nitrosourea containing DNA alkylating agents. 
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Figure 1.5: General mechanism of action of N-nitrosourea based DNA alkylators. 
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Another example of a classical DNA alkylating agent used for cancer therapy is 
busulfan which is a dimesylate derivative of 1,4-butanediol (Figure 1.6).   
 
Figure 1.6: Structure of busulfan. 
In the presence of a strong nucleophilic atom such as the N7 nitrogen atom of 
guanine, the mesylate leaving group can be nucle.ophilicly displaced in SN2 fashion to 
form a covalent linkage.  The presence of two mesylate leaving groups causes 
crosslinking of the two DNA strands resulting in damage to DNA and cell death 
pathways (Figure 1.7).
40-43
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Figure 1.7: General mechanism of action of busulfan. 
1B. Platinum based alkylating-like DNA interacting agents 
Alkylating-like agents, including platinum based drugs interact with DNA to 
make covalent bonds, however these drugs do not have any alkyl groups to alkylate DNA 
in a classical way. Some of the examples of platinum based clinical and pre-clinical 
anticancer agents are listed in (Figure 1.8). 
 
Figure 1.8: Examples of platinum based DNA interacting agents. 
Cisplatin has two leaving groups in the form of chlorines.  One of the chlorides is 
replaced by H2O in vivo to provide the aqua-complex [PtCl(NH3)2H2O]
+
 (Figure 1.9).  
This species undergoes further nucleophilic displacement by two guanine nucleobases on 
the same strand of DNA to form [PtCl(guanine-DNA)2(NH3)2]
+
 (Figure 1.9).
44
  Although 
many types of cisplatin-DNA adducts are reported, the predominant one involves 1,2-
intrastrand crosslinks with guanine bases d(GpG).  The mechanisms of action of other 
9 
 
platinum drugs are similar to that of cisplatin.  In these cases, the reactive chloride ions 
are replaced with more stable Pt-O bonds (Figure 1.9).
44
 
 
Figure 1.9: General mechanism of action of platinum based DNA interacting agents. 
1C. Non-classical DNA interacting agents 
Non-classical alkylating agents include hydrazine based procarbazene and 
triazene based dacarbazine and temozolomide (Figure 1.10).  Again, these drugs act as 
electrophiles for the alkylation with nucleophilic DNA.  However, the mechanism of 
10 
 
action and metabolic activation are different from that of classical alkylating nitrogen 
mustards and platinum agents.  Hence, they are listed as non-classical alkylating agents. 
Figure 1.10: Examples of non-classical DNA alkylating agents. 
Temozolomide is a lipophilic prodrug of dacarbazine.  It is highly orally 
bioavailable and due to its small size and high lipophilicity it crosses the blood-brain-
barrier with high efficiency (30% brain versus blood plasma). It undergoes metabolic 
activation to reactive methyl triazino imidazole carboxamide (MTIC) (Figure 1.11).  
This species further generates reactive electrophilic units which alkylate at N7 and O6 
positions of guanine residues, and N3 of adenine (Figure 1.12).
45-46
 This results in 
cellular apoptosis due to the failure of cellular repair mechanisms due to alkylated DNA. 
 
Figure 1.11: General mechanism of action of temozolomide. 
11 
 
 
Figure 1.12: Sites of alkylation of temozolomide. 
1D. DNA topoisomerase inhibitors 
 Other classes of antineoplastic agents that do not directly alkylate or bind to 
nitrogenous bases, but interact with and disrupt DNA functions include topoisomerase 1 
and 2 inhibitors (Figure 1.13 and 1.14).  In these cases, the flat topology of the molecule 
helps intercalate with the DNA strands, and the polar functional groups form a tight 
hydrogen bonding with phosphodiester backbone of DNA. 
 
Figure 1.13: Examples of topoisomerase 1 inhibitors. 
12 
 
 
Figure 1.14: Examples of topoisomerase 2 inhibitors. 
During DNA replication and transcription, DNA coding machinery causes an 
over-winding ahead of the replication fork that needs to be relaxed in order to release the 
torsional strain of the supercoiled DNA strand.  Topoisomerase 1 and 2 are responsible 
for the unwinding of DNA by cutting either one or both strands respectively. Inhibitors of 
such action cause high levels of genomic instability due to high strain near DNA 
replication and transcription machinery, and further leading to DNA damage and cell 
death pathways. 
47-48
 
Introduction of above mentioned DNA alkylators and other DNA interacting 
agents has tremendously improved the therapeutic outcome for a wide variety of cancers.  
13 
 
However, due to their non-selectivity they suffer from significant side effects including 
teratogenicity, severe myelosuppression, and permanent damage to the immune system. 
Hence, the development of novel DNA alkylators with high structural tunability and 
different mode of action with fewer side effects are highly required.  In this regard, we 
chose to explore the potential of an important C-C bond forming Baylis-Hillman (BH) 
reaction.  This reaction is very simple to perform, and by mixing an aldehyde with 
electron withdrawing group substituted ethylenes such as methyl acrylate, methyl vinyl 
ketone, and acrylonitrile in the presence of a nucleophilic base 1,4-
diazabicyclo[2.2.2]octane (DABCO) provides functionalized allyl alcohols in one step 
(Scheme 1.1). 
49-58
 
 
Scheme 1.1: Baylis-Hillman reaction. 
This reaction is highly atom efficient and typically requires no solvent and can be 
performed at room temperature.  The acetates of product BH alcohols can be isomerized 
with various nucleophiles in SN2’ fashion to provide further functionalized structural 
synthons (Scheme 1.2).  
14 
 
 
Scheme 1.2: SN2’ capability of BH acetates. 
The BH alcohols can also be converted into allyl bromides by reacting them with 
HBr/H2SO4 or PBr3 (Scheme 1.3). 
 
Scheme 1.3: Synthesis of BH-Bromide 
The BH bromide 1 is an intriguing structural intermediate and provides three 
opportunities for nucleophilic substitutions.  BH bromide 1 can undergo a direct 
nucleophilic substitution in SN2 fashion, allylic rearrangement in SN2’ mode, and 1,4 
addition reaction (Figure 1.15). 
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 Figure 1.15: SN2, SN2’, and 1,4 addition capabilities of BH bromide 1. 
 
1E. Utilization of BH bromides in organic synthesis 
The formaldehyde derived BH bromide 1 and the benzaldehyde derived BH 
bromide 2 (Figure 1.16) have been extensively utilized for indium, zinc, and titanium 
and other metal based nucleophilic Barbier type allylation reactions to obtain allyl 
alcohol 3 (Scheme 1.4).
59-68
   
 
Figure 1.16: BH Bromides 
 
Scheme 1.4: Barbier allylation of carbonyl compounds with BH bromides. 
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Conversely, they have also been used as electrophiles for nucleophilic C, N, O 
and S alkylations for a wide variety of structurally interesting natural and unnatural 
products.  They have also been explored for making a wide variety of medicinally 
important small molecules as anticancer, antibacterial, and pharmacological probes.  
Some of the applications of BH bromides 1 and 2 have been delineated below. 
 
1E.1.Diastereoselective alkylation of aspartic acids with BH bromides 
Hanessain et al. reported an anti-steroselective (85%) alkylation of N-CBz 
aspartic acid 4 using BH bromide 1 to provide the corresponding alkylated product 5 and 
6 (85%:15%) in 87% yield (Scheme 1.5).
69
 
 
Scheme 1.5: Diastereoselective alkylation of aspartic acids with BH bromides 
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1E.2. Synthesis of BC-ring system of natural alkaloid tuberostemoninol using BH 
bromide 
Williams and Jia reported the utilization of BH bromide 1 in the BC-ring system 
of natural alkaloid tuberostemoninol 6 (Figure 17). Alkylation of diphenyl morpholine 7 
with BH bromide 1 in the presence of potassium bicarbonate in DMF provides the SN2 
substituted N-alkylated product 8.  Subsequently, 8 was converted into the BC-ring 
synthon of tuberostemoninol 9 in several steps (Scheme 1.6).
70
  
 
Figure 1.17: Structure of tuberstemoninol. 
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Scheme 1.6: Synthesis of BC-ring system of natural alkaloid tuberostemoninol using BH 
bromide 1  
1E.4. Synthesis of substituted quinoziline-4-ones with BH bromide 
 Spring et al. utilized BH bromide for N-alkylation of 6-bromo-2-pyridone to 
provide the N-alkylated product 11.  Bromide in 11 was coupled under Stille conditions 
using Pd2(dba)3 and allyl or methallyl tin reagents (12 or 13) to afford the diene products 
14 or 15.  These products were cyclized using ring closing metathesis reaction with 
Grubb’s second generation catalyst to obtain substituted quinoziline-4-ones 16 or 17 
(Scheme 1.7).
71
  
 
Scheme 1.7: Synthesis of substituted quinoziline-4-ones with BH bromide 1. 
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1E.5. Synthesis of polycyclic γ-lactams utilizing BH bromide 
 Synthesis of polycyclic γ-lactams was achieved under metal free conditions via 
radical cyclization of 1,6-eneynes.  The required eneynes were conveniently synthesized 
via alkylation of tosylamides with BH bromide followed by DCC mediated coupling with 
propargylic acids (Scheme 1.8). 
72
  
 
 
Scheme 1.8: Synthesis of polycyclic γ-lactams utilizing BH bromide 1. 
1E.6. Synthesis of (S)-(3-benzyl-3-methyl-2,3-dihydrobenzofuran-6-yl)-piperidin-1-
yl-methanone utilizing BH bromide 
 Naguib and Luo synthesized piperidinyl methanone via O-alkylation of piperidine 
amide 18 with BH bromide 1 under basic conditions to obtain compound 19.  19 was 
subsequently converted to (S)-(3-benzyl-3-methyl-2,3-dihydrobenzofuran-6-yl)-
piperidin-1-yl-methanone 20 via a series of steps (Scheme 1.9).
73
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Scheme 1.9: Synthesis of (S)-(3-benzyl-3-methyl-2,3-dihydrobenzofuran-6-yl)-piperidin-
1-yl-methanone using BH bromide 1. 
1E.7. Synthesis of BH bromide derived peptidomimetics  
Ostaszewski et al. reported the synthesis of novel peptidomimetic inhibitors of 
thioredoxin−thioredoxin reductase system via O-alkylation of substituted cesium 
benzoates with BH bromide 1 and BH bromide derived peptidomimetic analogs 21 to 
provide BH product 22 and BH peptidomimetic product 23 (Scheme 1.10). 
74
   
 
Scheme 1.10: Synthesis of BH bromide derived peptidomimetics. 
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1E.8. Synthesis of 3-benzylidene-pyrrolidine-2,5-dione using BH bromide 
 3-benzylidene-pyrrolidine-2,5-dione have been synthesized from BH bromide 2 
via nucleophilic displacement of bromide with cyanide in SN2 fashion to obtain 
compound 24.  followed by conversion of the corresponding nitriles to amide 25 and base 
promoted cyclization to obtain 3-benzylidene-pyrrolidine-2,5-dione product 26 (Scheme 
1.11).
75
  
 
Scheme 1.11: Synthesis of 3-benzylidene-pyrrolidine-2,5-dione using BH bromide 2. 
  
1E.8. Synthesis of olefinic 1,5-dicarbonyl compounds with BH bromide  
Kim et al. synthesized olefinic 1,5-dicarbonyl compounds via C-alkylation of BH 
bromide 2 with allyl substituted 1,3 dicarbonyl compound 27 followed by Pd-mediated 
decarboxylative protonation of compound 28 provided 1,5-dicarbonyl compound 29 
(Scheme 1.12).
76
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Scheme 1.12: Synthesis of olefinic 1,5-dicarbonyl compounds with BH bromide 2. 
1E.9. Synthesis of indoleazocines utilizing BH bromide 
Batra et al. synthesized indoleazocine 32 starting with alkylation of trypatamine 
30 with BH bromide 2 in the presence of trimethylamine .  The corresponding N-
alkylated product 31was further converted into respective indoleazocine 32 by a series of 
steps (Scheme 1.13).
77
 
 
Scheme 1.13: Synthesis of indoleazocines utilizing BH bromide 2. 
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1E.10. Synthesis of tricyclic tetrahydroquinoline using BH bromide 
N-alkylation of N-tosylaminobenzaldehyde 33 with BH bromide 2 under basic 
conditions provided the product 34.  Treatment of 34 with hydroxyl amine afforded the 
aldoxime 35 which was directly treated with NCS and trimethylamine to obtain the 
tricyclic tetrahydroquinoline 36 via an intramolecular 1,3-dipolar nitrile oxide 
cycloaddition reaction. (Scheme 1.14).
78
  
 
Scheme 1.14: Synthesis of tricyclic tetrahydroquinoline using BH bromide 2. 
 
 
 
 
24 
 
1E.11. Synthesis of thiol-sensitive probes using BH bromide 
BH-bromide 2 was O-alkylated with various phenols 36a-f to afford 
corresponding phenacrylate derivatives 37a-f.  These were used as thiol sensitive probes 
for biological applications (Scheme 1.15).
79
  
 
Scheme 1.15: Synthesis of thiol-sensitive probes using BH bromide 2. 
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1E.12 Synthesis of dinapthyl chromanone utilizing BH bromide 
Kankam et al. synthesized methylene-dinaphthyl bis-chromanones starting from 
38 and BH bromide 2.  The esters in alkylated product 39 were hydrolyzed to 
corresponding carboxylic acids in 40 which were subsequently cyclized to corresponding 
dinapthyl chormanone 41 (Scheme 1.16).  The product chomanone 41 was tested against 
several bacterial strains with good zone of inhibition.
80
 
 
Scheme 1.16: Synthesis of dinapthyl chromanone utilizing BH bromide 2. 
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1E.13 Synthesis of isothiouronium salts using BH bromide  
Treatment of thiourea 42a and alkyl/aryl substituted thioureas 42b-c with BH 
bromide  2 provided S-allylic isothiouronium salts 43a-c respectively.  These thiourea 
salts were evaluated against a leukemia cancer cell line L1210 with moderate to good 
activity (Scheme 1.17).
81
  
 
Scheme 1.17: Synthesis of isothiouronium salts using BH bromide 2. 
  
 
 
 
 
27 
 
1E.13 Synthesis of allylic azides, thiocyanates, isothiouronium salts from BH 
bromide 
Sa et al. utilized BH bromide 2 as a template to react N3, SCN, and thiourea based 
nucleophiles in SN2 fashion to obtain the corresponding allylic azides, thiocyanates, 
isothiouronium salts 44a-c respectively.  The isothiouronium salt 44c was treated with 
acetic anhydride to obtain the acetylated product 45 (Scheme 1.18).  These structurally 
diverse products were evaluated as antitubercular agents with MIC values ranging from 
low to high micromolar activity against mycobacterium tuberculosis strain Mtb H37Rv.
82
 
 
Scheme 1.18: Synthesis of allylic azides, thiocyanates, isothiouronium salts from BH 
bromide 2. 
  
 
We envision the utilization of BH bromides 1 and 2 to develop novel DNA based 
alkylators because of their versatility as electrophiles and nucleophiles, and their ability 
28 
 
to accept nucleophiles in SN2, SN2’, and 1,4 addition fashion.  The reactivity of bromides 
1 and 2 to act as electrophiles for potential interaction with cellular components form the 
basis for the current thesis. 
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Results and Discussion 
As described in the introduction, the BH bromides 1 and 2 (Figure 2.1) have been 
extensively utilized as nucleophiles in metal mediated Barbier type allylations and also as 
electrophiles for C, N, O and S alkylations for the synthesis of a wide variety of structurally and 
biologically interesting small molecules (Figure 1.15 introduction).
1-24
  Mereddy’s group has 
also been working on the utilization of BH bromides 1, 2, and 3 as nucleophiles and also as 
electrophiles for the synthesis of medicinally important small molecules (Figure 2.1).
25-27
  
 
Figure 2.1:  Baylis-Hillman (BH) bromides  
 Using BH bromides 1 and 3 as nucleophiles, Mereddy et al. carried out Zn based Barbier 
allylations on o-formyl phenyl boronic acids to synthesize functionalized benzoxaboroles 4 and 5 
as potential antimicrobial agents.
25
  The reaction took place in a highly diasteroselective (syn) 
manner with BH bromide 3 to obtain diastereometrically pure compound 5 (Scheme 2.1). 
 
Scheme 2.1: Synthesis of functionalized benzoxaboroles from BH bromides. 
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 BH bromides 1 and 3 was also utilized as electrophiles for the synthesis of α-methylene-
β-substituted-γ-carboxy-γ-lactams. Here, the nucleophiles generated from α-amino ester based 
imines attacked the BH bromides 1 and 3 in SN2’ fashion to provide the functionalized 
pyroglutamates in a single step and in highly diastereoselctive fashion (Scheme 2.2).  This 
methodology was applied for the synthesis of fused [3.2.0.] heterobicyclic γ-lactam-β-lactones 
and γ-lactam-γ-lactones (Scheme 2.3).26  
 
Scheme 2.2: Synthesis of α-methylene-β-substituted-γ-carboxy-γ-lactams 
Scheme 2.3: Synthesis of fused [3.2.0.] heterobicyclic γ-lactam-β-lactones and γ-lactam-γ-
lactones. 
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More recently, Mereddy’s group exploited the SN2/SN2’ nature of BH bromides 1 and 2 
for the synthesis of quaternary ammonium curcuminoids as potential anticancer agents.  The 
curcuminoids generated from piperizinyl benzaldehydes were treated with BH bromides 1 and 2 
to provide quaternary ammonium curcuminoids 6 and 7 (Scheme 2.4).  All the synthesized 
compounds were found to be highly water soluble and the BH derived quaternary ammonium 
salts acted as leaving groups and interacted as electrophiles with nucleophilic cellular components 
in SN2/SN2’ fashion to provide moderate to good cell proliferation inhibition properties.
27
 Further 
biological studies of these compounds revealed that they were well tolerated in healthy mice and 
good tumor growth inhibition properties were observed in a pancreatic cancer tumor model in 
athymic nude mice (Figure 2.2 and 2.3). 
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Scheme 2.4: Synthesis of BH bromide derived water soluble quaternary ammonium 
curcuminoids. 
 
Figure 2.2: In vivo Systemic toxicity study of BH derived curcuminoid 6 in healthy CD-1 mice. 
 
Figure 2.3: In vivo anticancer efficacy study of BH derived curcuminoid 6 in a MIAPaCa-2 
xenograft model in athymic nude mice. 
Fascinated by the highly electrophilic nature of BH bromides 1 and 2, we sought to 
explore the potential of these bromides as alkylators of DNA and other nucleophilic cellular 
components for anticancer applications.  In vitro cell proliferation inhibition studies of the 
bromides 1 and 2 against several cancer cell lines (MDA-MB-231, 4T1, MIAPaCa-2) using MTT 
assay indicated that these compounds exhibited moderate to good potency against all the cell lines 
tested.  However, these compounds were found to be chemically not stable enough at room 
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temperature to be developed as potential anticancer agents.  We also reasoned that the presence of 
very reactive allylic bromide system would be reactive with high metabolic vulnerability and this 
could potentially cause several side effects.  In the present work, we envisaged to synthesize less 
reactive and more stable 2-(alkoxycarbonyl)-allyl esters  from carboxylic acids and BH bromides  
to increase chemical and metabolic stability, and retain the intriguing SN2, SN2’, and 1,4 addition 
capabilities for interaction with nucleophilic cellular components (Schemes 2.5 and 2.6).  In these 
cases, the carboxylic acid group will act as a leaving group for either SN2 or SN2’ interactions 
with nucleophiles.  
 
Scheme 2.5: SN2/SN2’ capabilities of 2-(alkoxycarbonyl)-allyl esters. 
 
Scheme 2.6: 1,4-addition capability of 2-(alkoxycarbonyl)-allyl esters. 
The 2-(alkoxycarbonyl)-allyl ester template provides high structural tunability and we 
envisioned three reactive sites for structural variations to improve the biological activity, targeted 
delivery to the reactive site, metabolic stability, water solubility, and other pharmaceutical and 
pharmacological properties.  For example, attaching hydroxyethylpiperizine unit or a sugar unit at 
reactive carboxylic ester site should lead to high water solubility and reduce the metabolic 
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vulnerability of ester hydrolysis by plasma esterases.  We can also attach some of the 
endogeneous molecules and metabolites such as cholesterol, amino acids, folic acid, α-
tocopherol, fatty acids etc. This should lead to more targeted delivery to the tumor site due to the 
elevated requirement of these biosynthetic starting materials and cofactors for rapid cell 
proliferation of cancer cells (Figure 2.4). 
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Figure 2.4: Structural tunability and potential of 2-(alkoxycarbonyl)-allyl template for improving 
water solubility, metabolic stability, and targeted delivery.  
To test this hypothesis we first synthesized and evaluated the cancer cell proliferation 
inhibition properties of 2-(methoxycarbonyl)-allyl benzoate 8.  The required BH bromide 1 for 
the preparation of 8 was synthesized in two steps by BH reaction of formaldehyde and methyl 
acrylate in the presence of DABCO, and bromination of the resulting alcohol in HBr/H2SO4.  The 
crude bromide was vacuum distilled to obtain the pure BH bromide 1.  The 2-(methoxycarbonyl)-
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allyl benzoate 8 was synthesized by treating benzoic acid with BH bromide 1 in the presence of 
sodium carbonate in DMSO (Scheme 2.7).  The crude product was extracted with ether and 
water, and the pure product was obtained upon purification with silica gel column 
chromatography with ethyl acetate:hexanes (2%:98%). Allyl benzoate 8 has excellent room 
temperature stability as evidenced by no observable decomposition at room temperature for one 
month according to 
1
H NMR.   
 
Scheme 2.7: Synthesis of 2-(methoxycarbonyl)-allyl benzoate. 
Satisfied with the chemical stability, we then evaluated the in vitro cell proliferation 
inhibition on difficult to treat human triple-negative breast cancer cell line MDA-MB-231, 
murine metastatic breast cancer 4T1, and human pancreatic cancer cell line MIAPaCa-2 by 
utilizing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability 
assay. Cells cultured in 96-well plates were incubated with the test compounds for 72 h, and MTT 
values were expressed as percent of vehicle-only (control) wells. The IC50 value was calculated 
for each compound as the dose required to suppress the MTT signal to 50% of control values.  
Gratifyingly, compound 8 retained a comparable or higher biological potency to the parent 
bromo-congener 1 (Figure 2.5). 
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Figure 2.5: Cell proliferation inhibition (IC50) values of 8 and 1 in micomolar concentration. 
 This encouraging biological activity and chemical stability led us to carry out a detailed 
structure activity relationship study (SAR) of 2-(alkoxycarbonyl)-allyl esters from various 
carboxylic acids and BH bromides.  First, we utilized formaldehyde BH bromide 1 and reacted 
with various substituted aromatic carboxylic acids.  Electron donating derived 2-
(alkoxycarbonyl)-allyl ester examples included 4-N,N-dimethyl (9),  4-methoxy (10), 3,4,5-
trimethoxy (11), and piperonyl (12) benzoic acid esters, and  electron withdrawing examples 
included 4-nitro (13) and 4-cyano (14) carboxylic acid esters (Scheme 2.8 and 2.9).  The 
corresponding product 2-(alkoxycarbonyl)-allyl esters were efficiently synthesized from the 
respective carboxylic acids and BH bromide 1 under basic conditions and purified via silica gel 
column chromatography in good to excellent yields (Scheme 2.8 and 2.9). 
 
Scheme 2.8: Synthesis of 2-(alkoxycarbonyl)-allyl esters derived from EDG substituted benzoic 
acids. 
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Scheme 2.9: Synthesis of 2-(alkoxycarbonyl)-allyl esters derived from EDG substituted benzoic 
acids. 
 We then carried out cell proliferation inhibition studies (MTT assay) on compounds 9-14 
and found that both electron donating and electron withdrawing substituents on 2-
(alkoxycarbonyl)-allyl esters 9-14 exhibited similar potency against all three cell lines (Figure 
2.6).   
 
Figure 2.6: Cell proliferation inhibition (IC50) values of 9-14 in micomolar concentration. 
 To further understand the SAR of the α-carboxy allyl ester unit, we took unsubstituted 
benzoic acid as a representative example.  First, to understand the importance of the carboxy ester 
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group in providing biological activity, we synthesized simple allyl benzoate 15. Compound 15 
was readily obtained by treating sodium salt of benzoic acid with allyl bromide followed by 
purification by silica gel column chromatography (Scheme 2.10).  
 
 
Scheme 2.10: Synthesis of allyl benzoate.   
This compound is not capable of 1,4 addition and simple benzoate is a poor leaving group 
for SN2 and SN2’ reactions in the absence of α-carboxy carbonyl group.  As expected, compound 
15 did not retain any biological activity even at 100μM concentration.  This clearly exhibits the 
importance of the α-carboxy carbonyl group in providing SN2/SN2’ capability for interaction with 
cellular components to provide biological activity.  We then modified the alkoxy group in ester 
by replacing methyl with ethyl and butyl substituents.  The corresponding BH bromides 16 and 
17 were synthesized by performing BH reaction of ethyl and butyl acrylates with formaldehyde in 
the presence of DABCO, followed by bromination using HBr/H2SO4 to give corresponding BH 
bromides 16 and 17 (Scheme 2.11).  The pure 16 and 17 were obtained via silica gel column 
chromatography using hexane as the elutant.  The reaction of benzoic acid with BH bromides 16 
and 17 under basic conditions followed by silica gel column chromatography gave the 
corresponding 2-(ethoxy/butoxycarbonyl)-allyl esters 18 and 19 respectively in good yield 
(Scheme 2.11).  
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Scheme 2.11: Synthesis of 2-(ethoxy/butoxycarbonyl)-allyl esters 18 and 19. 
 
Figure 2.7: Cell proliferation inhibition (IC50) values of 18 and 19 in micomolar concentration. 
  Cell proliferation inhibition studies of 18 and 19 did not lead to any enhanced activity, 
and the methyl substituent was found to be the optimal structural moiety for biological activity 
(Figure 2.7).  Next, we sought to explore the importance of the double bond of 2-
(alkoxycarbonyl)-allyl esters, since our hypothesis involved the reaction of nucleophilic cellular 
components in an SN2’ and/or 1,4 addition fashion for which the double bond was a critical 
component.  Hence, we saturated the double bond in 8 by dihydroxylation using osmium 
tetroxide/NMO conditions to provide the corresponding diol 20 (Scheme 2.12).   
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Scheme 2.12: Synthesis and cell proliferation inhibition (IC50) values of 20 in micomolar 
concentration. 
As anticipated, diol 20 did not retain any biological activity, illustrating the importance of 
the carboxycarbonyl double bond in its interaction with nucleophilic cellular components and 
subsequent SN2, SN2’ and/or 1,4 addition for providing biological reactivity.  We further 
investigated the SAR of 2-(alkoxycarbonyl)-allyl ester template by introducing β-substitution on 
double bond by placing a phenyl group. The required β-phenyl substituted derivative 22 was 
synthesized from benzoic acid and methyl (Z)-2-(bromomethyl)-3-phenylacrylate, BH bromide 2.  
The corresponding BH bromide 2 was prepared by BH reaction of benzaldehyde with methyl 
acrylate in the presence of DABCO for one week.  Crude allyl alcohol 21 was extracted with 
ethyl acetate and water and purified using silica gel column chromatography with ethyl 
acetate:hexanes (10%:90%) as the elutant.  The allyl alcohol 21 was further brominated with 
HBr/H2SO4, and extracted with ether and water.  The crude product was then purified via silica 
gel column chromatography using hexanes as elutant to obtain methyl (Z)-2-(bromomethyl)-3-
phenylacrylate 2.  BH bromide 2 was then reacted with benzoic acid in the presence of Na2CO3 in 
DMSO and purified via silica gel column chromatography to obtain the β-substituted 2-
(alkoxycarbonyl)-allyl ester 22 (Scheme 2.13).  β-substitution resulted in a decrease in biological 
activity when compared to β-unsubstituted compound 8 (Figure 2.8). 
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Scheme 2.13: Synthesis of β-substituted 2-(alkoxycarbonyl)-allyl ester 22.  
 
Figure 2.8: Cell proliferation inhibition (IC50) values of 22 in micomolar concentration 
We then explored the SAR of expanded aromaticity of the carboxylic acid component by 
utilizing naphthalene and anthracene carboxylic acids.  Reaction of 1-napthoic acid and 9-
antharcenecarboxylic acid with BH bromide 1 under basic conditions efficiently provided 
corresponding 2-(alkoxycarbonyl)-allyl esters 23 and 24 in good yields (Scheme 2.14).  
Biological evaluation resulted in a decreased potency when compared to the monocyclic benzoic 
acid derivatives 8-14 (Figure 2.9).   
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Scheme 2.14: Synthesis of 2-(alkoxycarbonyl)-allyl esters 23 and 24 from naphthalene and 
anthracene carboxylic acids.  
 
Figure 2.9: Cell proliferation inhibition (IC50) values of 23 and 24 in micomolar concentration. 
Structurally modified alkyl and alkenyl 2-(alkoxycarbonyl)-allyl esters 25 and 26 derived 
from cinnamic acid and 4-phenylbutyric acid were also synthesized to evaluate the effect alkyl 
and alkenyl spacers on biological activity.  The required alkoxycarbonyl-allyl esters 25 and 26 
were synthesized by treating cinnamic acid and 4-phenyl butyric acid with BH bromide 1 under 
basic conditions and purified via silica gel column chromatography to obtain 25 and 26 (Scheme 
2.15). 
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Scheme 2.15: Synthesis of 2-(alkoxycarbonyl)-allyl ester 25 and 26 from cinnamic and 4-phenyl 
butyric carboxylic acids. 
Biological evaluation of 25 and 26 did not lead to decreased potency, illustrating the 
importance of aromatic carboxylic acid derived 2-(alkoxycarbonyl)-allyl esters for optimal 
biological activity (Figure 2.10). 
 
Figure 2.10: Cell proliferation inhibition (IC50) values of 25 and 26 in micomolar concentration. 
To increase the functionalization, we utilized di- and tri-carboxylic acids to synthesize di- 
and tri-functionalized 2-(alkoxycarbonyl)-allyl esters.  In this regard, derivatives 27-29 were 
synthesized using terephthalic acid, 2,6-pyridinedicarxoxylic acid, and trimesic acid respectively.  
These products 27-29 were conveniently synthesized by the reaction of stoichiometric equivalents 
BH bromide 1 with respective carboxylic acids 27-29 in the presence of Na2CO3 in DMSO, and 
were purified via silica gel column chromatography (Scheme 2.16).   
45 
 
 
Scheme 2.16: Synthesis of 2-(alkoxycarbonyl)-allyl ester 27, 28, and 29 from terepthalic acid, 
2,6-pyridinedicarboxylic acid, and trimesic acid.   
Biological evaluation resulted in significantly enhanced cell proliferation inhibition 
properties when compared to the monoesters of aromatic carboxylic acids (Figure 2.11).  For 
example, pyridine dicarboxylic acid derived 2-(alkoxycarbonyl)-allyl ester 28 exhibited cell 
proliferation inhibition IC50 values in the 3-6μM range when compared to mono allyl ester of 
benzoic acid derived 8 with IC50 values ranging from 12-35μM. 
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Figure 2.11: Cell proliferation inhibition (IC50) values of 27, 28, and 29 in micomolar 
concentration. 
To further expand the application of activity enhancing 2-(alkoxycarbonyl)-allyl esters, 
we employed clinically used chemotherapeutic agent chlorambucil 30 as a representative 
example.  Chlorambucil is clinically utilized to treat chronic lymphatic leukemia, Hodgkin’s 
disease, and other types of lymphomas.
28-30
 Although chlorambucil has good activity against 
leukemia’s and lymphomas, it does not exhibit any appreciable efficacy against solid tumor cell 
lines.  For example, chlorambucil does not exhibit any cell proliferation inhibition properties up 
to 100μM against MDA-MB-231, 4T1, or MIAPaCa-2 cell lines.  Reaction of chlorambucil 
carboxylic acid 30 with BH bromide 1 under basic conditions efficiently afforded compound 31.  
Compound 31 showed enhanced biological activity when compared to parent chlorambucil 30, 
with IC50 values in the range of 49-83μM against all three cell lines (Figure 2.12).   
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Figure 2.12: Synthesis and cell proliferation inhibition (IC50) values of chlorambucil 30, and 
compound 31 in micomolar concentration. 
 The chlorambucil alkoxy allyl ester 31 is highly interesting because it has dual reaction 
sites for interaction with cellular DNA with nitrogen mustard unit via aziridinium intermediate, 
and alkoxyester as SN2/SN2’/1,4 addition structural subunit (Figure 2.12).   
 It is interesting to note that parent BH alcohol 21 did not show any appreciable biological 
activity, but the corresponding acetate 32 derived from alcohol 21 and benzoyl chloride resulted 
in cell proliferation inhibition properties albeit at lower concentrations than the lead 2-
(alkoxycarbonyl)-allyl esters.  The biological activity of BH acetate 32 could be attributed to the 
leaving group capacity of allyl benzoate in the presence of cellular nucleophiles (Figure 2.13).   
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Figure 2.13: Cell proliferation inhibition (IC50) values of 21 and 32 in micomolar concentration. 
From these results, compounds 10 and 28 derived from 4-methoxybenzoic acid and 2,6-
pyridine dicarboxylic acid were designated as lead compounds based on their potency in cell 
proliferation inhibition and mono-and di-functionalization.  Further mechanistic studies of these 
two compounds were performed, starting first with the effect of compound treatment on cellular 
morphology based on phase contrast microscopy.  MDA-MB-231 cells were plated on culture 
plates and exposed to compound 10 and 28 for 6 and 48 hours at concentrations equal to 1X, 2X, 
and 4X their IC50 values for cell proliferation inhibition; equating to 8, 16, and 32μM for 
compound 10, and 4, 8, and 16μM for compound 28, respectively.  For both compounds, the 1X 
IC50 concentrations led to little to no morphological effects at either time point.  However, for 
compound 10 cell rounding became evident at the 2X and 4X concentration after 6 hours of 
treatment which progressed to cell detachment and clustering after 48 hours (Figure 14).  For 
compound 28, noticeable cell rounding after 6 hours was apparent at the 4X concentration, which 
also advanced to clustering at the 48 hour time point (Figure 2.14).  It was previously reported 
that rounding and clustering of cells were observed due to damage of cell integrins, cytoskeletal 
elements, and cadherins when treated with well characterized alkylating agents.
31
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Figure 2.14: Phase contrast imaging of MDA-MB-231 cells after treatment with differing 
concentrations of compound 10 and 28. All images were captured using the same magnification 
(see scale bar). Note cell rounding at the higher compound concentrations. 
The make-up of DNA includes nucleophilic components that render the bio-
macromolecule highly susceptible to alkylation by electrophilic agents.  Such agents can react 
with nucleophilic ring nitrogens or exocyclic oxygens to produce a wide variety of DNA-
adducts.
32
  Both mono- and bifunctional alkylating agents can result in numerous complex 
cellular effects including DNA-strand breaks, cell cycle arrest and/or perturbation, and 
programmed cell death pathways.
33-34
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Due to the electrophilic nature of compounds 10 and 28, the morphological effect of 
nuclear organization and cell cycle regulation were examined via immunofluorescent microscopy.  
MDA-MB-231 cells were plated on cover slips and treated with compound 10 and 28 at their IC50 
value of cell proliferation inhibition.  Cells were then fixed with 2% paraformaldehyde, and then 
labeled with Hochest dye to label nuclei.  In some cases, cells were pulsed with 
bromodeoxyuridine (BrdU) to examine actively replicating nuclei of cells in S-phase.   In control 
cultures, most nuclei exhibited a normal organized appearance, with a few nuclei exhibiting small 
micro nuclei.  MDA-MB-231 exhibits a high level of genomic instability, and as a result has a 
small level of irregular nuclear bodies.  In contrast, treatment with compound 28 for 24 hours 
resulted in a high percentage of nuclei exhibiting a large level of irregular nuclear bodies and 
micronucleation indicative of karyorrhexis (Figure 2.15).  Compound 10 led to a more modest 
effect (data not shown).  Well characterized and clinically used alkylating agents such as 
cisplatin, carboplatin, ifosfamide, carboplatin, thiotepa, and N-methyl-N-nitrosourea have also 
been shown to induce such nuclear fragmentation in numerous cell types.
34-35
  
 
Figure 2.15: MDA-MB-231 cells treated with vehicle (DMSO) or compound 28 for 24 h, and 
subsequently pulsed with BrdU to identify replicating (S-phase) cells, and counterstained with 
Hoechst dye to label all nuclei. Hoechst fluorescence is shown in blue, and BrdU antibody 
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labeling is shown in red. Inset: higher magnification of fragmented nuclear bodies indicative of 
karyorrhexis in a cell treated with 28. 
Next, we sought to further understand the effect of compounds 10 and 28 on the 
molecular level by employing western blotting techniques.  A widely used and established 
indication of DNA damage and repair pathway activation is histone H2AX phosphorylation, 
forming γ-H2AX.  Histone H2AX plays major roles in the cells response to DNA damage, and is 
usually activated upon DNA single and double strand breaks.
36-37
 The ability of compounds 10 
and 28 to induce H2AX phosphorylation was evaluated by utilizing a phospho-specific antibody.  
MDA-MB-231 cells were treated with compound 10 and 28 for 6 hours at 1X, 2X and 4X their 
respective IC50 of cell proliferation inhibition and cells were harvested.  Subsequently, the 
harvested cells were blotted for γ-H2AX using a phospho-specific antibody.  High levels of 
genomic instability observed in MDA-MB-231 cells lead to a high level of intrinsic DNA 
damage, and hence a high level of H2AX phosphorylation.  There was a clear increase in the γ-
H2AX signal at the high end concentrations.  Interestingly, the signal is comparable to that 
observed in MDA-MB-231 cells treated with well characterized alkylating agent mitomycin c 
(MC) (Figure 2.16).   
Another important molecular response to DNA damage repair is the employment of 
enzyme poly (ADP-ribose) polymerase (PARP).  Upon DNA damage, PARP is upregulated and 
recruited to the sites of damage and further initiates the DNA repair process.
38
  Hence, PARP is 
activated by DNA alkylating agents.  Depending on the extent of DNA damage, PARP activation 
can be followed by cell death pathways such as apoptosis or necrosis, and upon apoptosis 
activation, PARP is an early target for caspase induced cleavage.
39
  In fact, cleavage of full length 
PARP is often used as an indication of caspase activation in apoptosis.  Western blotting indicates 
an initial activation of PARP at low end concentrations of compound 10 and 28 at a similar extent 
as MC, followed by a decrease in the PARP signal at higher concentrations of 10 and 28.  These 
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results suggest initial activation upon alkylator induced DNA damage, followed by the activation 
of apoptosis at higher drug concentrations (Figure 2.16). 
 
Figure 2.16: Western blot analysis of MDA-MB-231 whole cell lysates treated with differing 
concentrations of compounds 10, 28, DMSO (vehicle control) or Mitomycin C (MC) as an 
example of a well-characterized alkylating compound. γ-H2AX was probed after six hours 
whereas PARP-1 was probed after 48 h of treatment with 10 or 28. 
Cell cycle effects of compounds 10 and 28 were examined using BrdU uptake 
experiments and cyclin D1 expression changes.  Cyclin D1 is an important regulating enzyme, 
and governs the cells G1 to S transition.  Proteolytic degradation of cyclin D1 is an important 
mechanism of cell cycle regulation and hence, the quantity of the enzyme fluctuates throughout 
different phases of the cell cycle.
40-41
  Western blotting indicated an initial increase in the 
expression of cyclin D1 at low to intermediate concentrations of 10 and 28, followed by a 
decrease at higher concentrations (Figure 2.17).   
 
Figure 2.17: Western blot analysis of MDA-MB-231 whole cell lysates treated with differing 
concentrations of compounds 10, 28, DMSO (vehicle control) or Mitomycin C (MC) as an 
53 
 
example of a well-characterized alkylating compound.  Cyclin D1 was probed after 48 h of 
treatment with 10 or 28. 
The increase in cyclin D1 expression could indicate cell cycle arrest at low levels of 
cyclin D1, and its following decrease may be indicative of an apoptotic response, which has also 
been supported by the decrease in PARP signal.   
 The effect of compounds 10 and 28 on DNA replication and synthesis was examined 
using BrdU uptake experiments through immunofluorescent microscopy.  MDA-MB-231 cells 
were plated on cover slips, treated with compound 10 or 28 for 24 hours, pulsed with BrdU for 
one hour, and fixed for epifluorescent observation.  At low concentrations of 10 or 28, little 
change in BrdU positive (S-phase) cells was observed.  At higher concentrations of 28, however, 
there was a clear decrease in actively replicating cells.  Interestingly, cells exhibiting high levels 
of nuclear fragmentation and karyorrhexis were BrdU negative, indicating karyorrhectic induced 
cell cycle cessation in the presence of compound 28 (Figure 2.15).  
Based on these results, compound 28 has been designated as the lead candidate 
compound for further in vivo studies of systemic toxicity and chemotherapeutic efficacy based on 
its in vitro potency in the assays described above.  Initially, compound 28 was examined for its 
systemic toxicity in CD-1 mice.  12 healthy CD-1 mice were divided into two groups (n=6):  
Group 1 was administered compound 28 (20mg/kg) and group 2 was administered vehicle only 
(control) intraperitoneally once daily six days a week for a total of 14 days. This study indicated 
that compound 28 was well tolerated with no apparent side effects at acceptable therapeutic dose 
regimens based on normal weight gains and behavior when compared to control group (Figure 
2.18).  
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Figure 2.18: Systemic toxicity study of compound 28 in CD-1 mice 
Compound 28 was then tested for its anticancer efficacy in a triple-negative breast cancer 
MDA-MB-231 xenograft model in NOD SCID mice.  Cells were inoculated into the right flank of 
mice and treatment was initiated when the tumor volume reached ~150mm
3
.  Mice were 
randomly designated into three groups (n=7) based on average tumor volume.  Group 1 was 
administered compound 28 (20mg/kg) three times a week, Group 2 was administered clinically 
used breast cancer drug doxorubicin (0.5mg/kg) five times a week, and Group 3 was administered 
vehicle.  Tumor volumes and body weights were recorded every third day, and at the end of the 
study, mice were euthanized based on the institution of animal care and use committee (IACUC) 
guidelines.  It was observed that compound 28 led to a statistically significant 55% decrease in 
tumor volume and a 41% decrease in tumor weight when compared to the control group.  
Comparatively, doxorubicin led to a 49% decrease in tumor volume and 28% decrease in tumor 
weight when compared to the control (Figure 2.19).   
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Figure 2.19: Tumor growth inhibition study of compound 28 in a MDA-MB-231; xenograft 
model. 
Conclusion and Future Directions 
In conclusion, several structurally diverse 2-alkoxycarbonyl-allyl esters were synthesized 
from BH bromides.  SAR studies indicated that β-unsubstituted 2-(methoxycarbonyl)-allyl esters 
derived from aromatic carboxylic acids were optimal, the double bond was required for biological 
activity, and di- and tri-functionalized analogues had enhanced activity when compared to the 
mono esters. The cell proliferation inhibition properties were evaluated utilizing the MTT assay, 
with several derivatives exhibiting inhibition at low micromolar concentration.  Preliminary in 
vitro studies indicated DNA damage and cell cycle effects that are consistent with alkylation.  
Finally, systemic toxicity studies indicated that compound 28 was well tolerated in healthy CD-1 
mice, and exhibited statistically significant tumor growth inhibition properties in a MDA-MB-231 
xenograoft model.  Due to the ease of synthesis, potential for product diversity, structural 
tunability, novelty of the mechanism of action, and encouraging in vitro and in vivo activity, the 
compounds reported in this thesis are promising to be further developed as anticancer agents.   
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As a disclaimer, we do not discredit the ability of these molecules to interact with 
nucleophilic cellular components other than DNA.  Several other nucleophilic biomolecules 
including amino acids such as cysteine, serine, threonine, and tyrosine can potentially react with 
2-(alkoxycarbonyl)allyl esters in SN2 or SN2’ fashion.  Hence, molecules presented in this thesis 
have the potential to react with proteins in similar fashion as DNA.  Further, mitochondrial DNA, 
although compartmentalized by the inner and outer mitochondrial membranes, is also susceptible 
to alkylation by electrophilic 2-(alkoxycarbonyl)-allyl esters in SN2, SN2’, and 1,4 addition 
fashion.  Also, glutathione and N-acetyl cysteine have the capability to react with electrophilic 
xenobiotics for protective mechanisms, and could potentially react with presented compounds in 
nucleophilic fashion.  Although nuclear DNA is the most abundant nucleophile in the cell, and 
preliminary mechanisms of action support DNA alkylation, the intrinsic reactivity of molecules 
presented in this thesis may have cellular off-target effects.   
Future directions of this project will involve attaching the BH-bromide template to 
biologically relevant molecules to achieve the targeted delivery to the tumor sites which would 
minimize the potential side effects expected from non-targeted therapeutic agents.  Some of the 
other goals also involve improving the water solubility of the compounds by attaching 
piperizinyl, amino alkyl N,N-dialkyl groups etc.  Some of these aspects have been described in 
Figure 2.4. 
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Experimental 
Materials and Methods 
Benzoic Acid (Fisher Scientific), trimesic Acid (Sigma-Aldrich), formaldehyde (Sigma-
Aldrich), methyl acrylate (Sigma-Aldrich), phthalic acid (Sigma-Aldrich), 2, 6 
pyridinedicarboxyllic acid (AKSci), cinnamic acid (Fisher Scientific), sodium carbonate 
(Fisher-Scientific), osmium tetroxide (Sigma-Aldrich), N-methyl morpholine N-Oxide 
(NMO, Sigma-Aldrich), 1-napthoic acid (AKSci), 9-anthracene carboxylic acid (AKSci), 
4-phenylbutyric acid (Fischer Scientific).  All other chemicals were of reagent grade 
quality and purchased from Sigma-Aldrich (St. Louis, MO). The 
1
H- and 
13
C-NMR 
spectra were plotted on a Varian Oxford-500 spectrometer. High-resolution mass spectra 
(HRMS) were recorded using a Bruker micrOTOF-Q III ESI mass spectrometer. 
Elemental analysis (CHN) results were obtained from Atlantic Microlab services.  
Representative procedure for the synthesis of 2-(alkoxycarbonyl)allyl esters 
To carboxylic acid (2 mmol) in DMSO (5 mL) was added Na2CO3 (6 mmol) and stirred 
for 15 min at room temperature. 2-(methoxycarbonyl) allyl bromide (2 mmol) was then 
added and reaction mixture was stirred for 2hr at room temperature. Upon completion 
(TLC), water (50 mL) was added and product was extracted with diethyl ether (3x50ml).  
Ether layer washed with saturated sodium bicarbonate (50 mL) to remove trace DMSO 
and unreacted acid.  Organic layer was then dried using anhydrous MgSO4 and filtered.  
Crude product was then concentrated under vacuum and pure compounds 5-14, 16-24 
were obtained via column chromatography (1:20 EtOAc:Hexanes) (65-90%). 
Synthesis of 2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl benzoate 
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To compound 5 (2 mmol) in acetone (10 mL) was added N-methylmorpholine-N-oxide 
(NMO) (5 mmol) and catalytic osmium tetroxide (0.02 mmol).  Reaction was stirred at 
room temperature for six hours. Upon completion (TLC), acetone was removed under 
reduced pressure and residue  obtained was diluted with 50 mL of water and the crude 
product was extracted with ethyl acetate (3x25mL) and purified via column 
chromatography (1:5, EtOAc:Hexanes) to obtain compound 15 (70%). 
Cell Culture  
MDA-MB-231 cells (ATCC) were grown in DMEM supplemented with 10% FBS and 
penicillin-streptomycin (50U/ml-50µg/ml). MIAPaCa-2 cells (ATCC) were cultured in 
DMEM supplemented with 10% FBS, 2.5% Horse Serum and penicillin-streptomycin 
(50U/ml-50µg/ml). 4T1 cells (ATCC) were cultured in RPMI-1640 supplemented with 
10% FBS and penicillin-streptomycin (50U/ml-50µg/ml). 
Fluorescent Labeling 
MDA-MB-231 cells (5x10
4
cells/mL) were seeded on glass coverslips and cultured for 
18-24hr.  Cells were then treated with compound 7, 22, or DMSO (vehicle control) for 24 
hours.  After exposure, cells were pulsed with bromodeoxyuridine (BrdU, 4μg/mL) for 1 
h.   Media was then aspirated and cells were fixed with 2% paraformaldehyde in 
phosphate-buffered saline (PBS) for 15 min.  Cells were rinsed with PBS containing 
0.05% Tween-20 (PBST), and subsequently treated with 2N HCl for 20 min at room 
temperature and again rinsed with PBST.  Cells were then blocked with normal goat 
serum (NGS) for 1 h at 37⁰C and incubated in a 1:500 dilution of BrdU antibody (G3G4, 
Developmental Studies Hybridoma Bank, Iowa City, IA) in PBST/5% NGS at 4⁰C 
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overnight.  Following incubation, cells were rinsed with PBST and exposed to Texas Red 
conjugated secondary goat-anti-mouse antibody (Jackson Immunoresearch, Malvern, PA, 
1:60 in PBST/5%NGS) and Hoechst (50μg/mL) for 1h at 37⁰C. After three PBST washes, 
coverslips were mounted with anti-fade media (0.5M CAPS pH 9.8, 80% v/v glycerol, 
0.1% w/v phenylene diamine, and 0.1% DABCO in PBS). Hoechst and BrdU labeled 
nuclei were then photographed using a Nikon TE2000 epifluorescent microscope; the 
images shown are representative of three separate experiments 
Western Blot analysis 
MDA-MB-231 cells (5x10
4
 cells/mL) were treated with compound 7, 22, Mitomycin C 
(positive control) or DMSO (negative control) for 6 and 48 hours and whole cell lysates 
were collected. After denaturation at 95 °C for 10 min in a SDS sample buffer (5% w/v 
sodium dodecyl sulfate, 10% v/v glycerol, 60mM Tris, pH 6.8), protein concentration 
was determined using bicinchoninic acid (ThermoScientific) and equal amounts of 
protein (20 μg) separated by electrophoresis in 8% or 12% polyacrylamide gels. Proteins 
were electrophoretically transferred to nitrocellulose membranes for 90 min at 100 V, and 
subsequently stained with Ponceau to assess transfer quality and verify equal protein 
loading.  After blocking the membranes with 10% w/v nonfat milk in PBST for 1 h at 
35⁰C, membranes were incubated overnight at 4 °C with rabbit anti-PARP (Santa Cruz 
H-250, 1:130), rabbit anti-Cyclin-D1 (Abcam AB16663, 1:260) or mouse anti-γH2AX 
(Upstate 05-636, 1:2500). Membranes were washed three times with PBST and incubated 
with the respective secondary goat anti-mouse IgG (1:2000) or goat anti-rabbit IgG 
(1:2000) horseradish peroxidase-conjugated antibodies (Jackson Immunoresearch). 
Membranes were again rinsed three times with PBST and were exposed to SuperSignal
®
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West Pico luminol enhancer solution and stable peroxide solution (ThermoScientific) for 
2 minutes and visualized with a Licor imager. Images shown are representative of three 
separate experiments. 
 
Ponceau-s stain of 8% SDS-PAGE of MDA-MB-231 cells exposed to compounds 7 and 
22 used for PARP-1 and Cyclin-D1 antibodies. 
 
 
Ponceau-s stain of 12% SDS-PAGE of MDA-MB-231 cells exposed to compounds 7 and 
22 used for γH2AX antibody. 
 
Ethical Considerations 
The experimental procedures involving animals that were conducted at the University of 
Minnesota Duluth was in compliance with the U.S. National Institutes of Health Guide 
for Care and Use of Laboratory Animals and approved by the Institutional Animal Care 
and Use Committee (IACUC). Studies with protocols 1311-31063A (systemic toxicity, 
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Figure 3A) and 1605-33796A (MDA-MB-231 xenograft, Figure 3B) were conducted at 
the University of Minnesota.  
In vivo systemic toxicity in CD-1 mice 
Five week old CD-1 mice (Charles River) were obtained and acclimatized for one week 
prior to treatment. Mice (n = 6) were grouped randomly based on average body weight. 
Group-1 was administered with compound 22 (20mg/kg) whereas group-2 was 
administered with vehicle intraperitoneally once daily, six days a week for a total of 14 
days of treatment. Mice body weights were recorded daily, and euthanized according to 
IACUC guidelines at the end of the study. A graph of days of treatment versus body 
weight±SEM was generated using GraphPad software. 
In vivo MDA-MB-231 xenograft model in SCID mice 
5x10
6
 cells MDA-MB-231 cells suspended in 1:1 matrigel-PBS were injected on right 
flank of female SCID mice (Jackson Laboratories). Treatment was initiated when the 
average tumor volume was ~150mm
3
. The mice were randomly assigned into groups 
(n=7) based on average tumor volume and average body weight. Tumors were measured 
with calipers every two or three days and tumor volumes were calculated using the 
formula V = (ab
2
)/2 where ‘a’ is the long diameter of the tumor and ‘b’ is the short 
diameter of the tumor. Mice were euthanized according to IACUC guidelines at the end 
of the study and tumors were isolated and weighed.  
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MDA-MB-231 Xenograft model.  Graphical representation of average tumor mass (g) 
following 14 days of treatment. 
 
 
Statistical Analysis 
Statistics were computed using GraphPad Prism version 6.0. Mann-Whitney test was 
used to compare the compound-treated and control groups for in vivo tumor xenograft 
studies. A P-value of < 0.05 was considered significant. 
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Spectral Characterization 
 
2-(methoxycarbonyl)allyl benzoate 
1
H NMR (500MHz, CDCl3): δ 8.07 (d, J = 8.5 Hz, 2H), 7.58 (t, J = 8.5 Hz, 1H), 7.45 (t, 
J = 8.0 Hz, 2H), 6.43 (s, 1H), 5.95 (s, 1H), 5.08 (s, 2H), 3.81 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.88, 165.62, 135.25, 133.11, 129.81, 129.62, 128.38, 
127.38, 62.75, 52.02 
Anal. Calcd for C12H12O4 (220.22): C 65.45, H 5.49 Found: C 65.51. H 5.57 
 
 
(E)-2-(methoxycarbonyl)-3-phenylallyl benzoate 
1
H NMR (500MHz, CDCl3): δ 8.07-8.05 (m, 3H), 7.57 (t, J = 7.5 Hz, 1H), 7.56-7.38 (m, 
7H), 5.21 (s, 2H), 3.86 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 167.41, 166.32, 145.85, 134.25, 133.07, 130.05, 129.75, 
129.67, 129.54, 128.82, 128.41, 126.66, 59.88, 52.38 
Anal. Calcd for C18H16O4 (296.32): C 72.96, H 5.44 Found: C 72.76. H 5.43 
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2-(ethoxycarbonyl)allyl benzoate 
1
H NMR (500MHz, CDCl3): δ 8.07 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 7.5 Hz, 1H), 7.47 (t, 
J = 8.0 Hz, 2H), 6.42 (s, 1H), 5.94 (s, 1H), 5.08 (s, 2H), 4.30-4.25 (q, J = 7.5 Hz, 2H), 
1.32 (t, J = 8.0 Hz, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.95, 165.22, 135.61, 133.14, 129.91, 129.67, 128.43, 
127.11, 62.86, 61.03, 14.17 
Anal. Calcd for C13H14O4 (234.25): C 66.66, H 6.02 Found: C 66.42. H 5.90 
 
 
2-(butoxycarbonyl)allyl benzoate 
1
H NMR (500MHz, CDCl3): δ 8.07 (d, J = 7.5 Hz, 2H), 7.58 (t, J = 7.5 Hz, 1H), 7.46 (t, 
J = 8.0 Hz, 2H), 6.42 (s,1H), 5.93 (s,1H), 5.08 (s, 2H), 4.22 (t, J = 6.5 Hz, 2H), 1.70-1.64 
(m, 2H), 1.45-1.37 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.95, 165.30, 135.62, 133.14, 129.89, 129.67, 128.41, 
127.22, 64.89, 62.90, 30.59, 19.16, 13.66 
Anal. Calcd for C15H18O4 (262.3): C 68.69, H 6.92 Found: C 68.45. H 6.97 
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2-(methoxycarbonyl)allyl 4-phenylbutanoate 
1
H NMR (500MHz, CDCl3): δ 7.30-7.17 (m, 5H), 6.37 (s, 1H), 5.85 (s, 1H), 4.82 (s, 
2H), 3.79 (s, 3H), 2.67 (t, J = 7.5Hz, 2H), 2.39 (t, J = 7.0Hz, 2H), 1.98 (quint, J =7.5Hz, 
2H) 
13
C NMR (125MHz, CDCl3): δ 172.82, 165.67, 141.27, 135.30, 128.48, 128.40, 127.61, 
126.02, 62.35, 52.04, 35.07, 33.48, 26.44 
HRMS (ESI) m/z: calc’d for C15H18O4 [M+H]
+
 : 263.1239, found 263.1306 
 
 
 
2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl benzoate 
1
H NMR (500MHz, CDCl3): δ 8.00 (d, J = 8.0 Hz, 2H), 7.58 (t, J = 8.0 Hz, 1H), 7.45 (t, 
J = 7.8 Hz, 2H), 4.53-4.47 (dd, 2H), 3.93-3.78 (m, 6H), 2.22 (br s, 1H) 
13
C NMR (125MHz, CDCl3): δ 173.17, 166.01, 133.39, 129.69, 129.34, 128.50, 66.22, 
64.69, 53.53, 42.67 
Anal. Calcd for C12H14O6 (254.08): C 56.69, H 5.55 Found: C 55.72, H 5.59 
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2-(methoxycarbonyl)allyl 4-nitrobenzoate 
1
H NMR (500MHz, CDCl3): δ 8.30 (d, J = 8.5 Hz, 2H), 8.23 (d, J = 8.0 Hz, 2H), 6.47 (s, 
1H), 5.98 (s, 1H), 5.12 (s, 2H), 3.83 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.45, 164.09, 150.64, 135.21, 134.76, 130.80, 128.52, 
123.58, 63.77, 52.18 
HRMS (ESI) m/z: calc’d for C12H11NO [M+H]
+
 : 266.0620, found 266.0659 
 
 
2-(methoxycarbonyl)allyl 4-cyanobenzoate 
1
H NMR (500MHz, CDCl3): δ 8.13 (d, J = 8.5 Hz, 2H), 7.74 (d, J = 8.5 Hz, 2H), 6.43 
(s, 1H), 5.94 (s, 1H), 5.07 (s, 2H), 3.80 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.47, 164.34, 134.78, 133.64, 132.28, 130.18, 128.44, 
117.89, 116.59, 63.64, 52.19 
Anal. Calcd for C13H11NO4 (245.23): C 63.67, H 4.52, N 5.71 Found: C 61.61, H 4.64, 
N 5.32 
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2-(methoxycarbonyl)allyl 4-methoxybenzoate 
1
H NMR (500MHz, CDCl3): δ 8.03 (d, J = Hz, 2H), 6.91 (d, J = Hz, 2H), 6.40 (s, 1H), 
5.95 (s, 1H), 5.05 (s, 2H), 3.88 (s, 3H), 3.77 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.69, 165.62, 163.53, 135.48, 131.70, 127.13, 122.22, 
113.67, 62.48, 55.41, 52.01 
Anal. Calcd for C13H14O5 (250.25): C 62.39, H 5.64 Found: C 62.21. H 5.62 
 
 
 
 
2-(methoxycarbonyl)allyl 3,4,5-trimethoxybenzoate 
1
H NMR (500MHz, CDCl3): δ 7.32 (s, 2H), 6.43 (s, 1H), 5.92 (s, 1H), 5.07 (s, 2H), 
3.92-3.91(two singlets for two peaks, 9H), 3.82 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.63, 165.54, 152.97, 142.45, 135.32, 127.38, 124.79, 
106.94, 62.86, 60.89, 56.24, 52.06 
Anal. Calcd for C15H18O7 (310.3): C 58.06, H 5.85 Found: C 57.53, H 5.81 
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2-(methoxycarbonyl)allyl 4-(dimethylamino)benzoate 
1
H NMR (500MHz, CDCl3): δ 7.93 (d, J = 9Hz, 2H), 6.64 (d, J = 9Hz, 2H), 6.38 (s, 
1H), 5.91 (s, 1H), 5.02 (s, 2H), 3.80 (s, 2H), 3.04 (s, 6H) 
13
C NMR (125MHz, CDCl3): δ 166.24, 165.86, 153.45, 135.82, 131.40, 126.65, 116.49, 
110.70, 61.98, 51.97, 40.03 
Anal. Calcd for C14H17NO4 (263.29): C 63.87, H 6.51, N 5.32 Found: C 63.64. H 6.48, 
N 5.24 
 
 
2-(methoxycarbonyl)allyl benzo[d][1,3]dioxole-5-carboxylate 
1
H NMR (500MHz, CDCl3): δ 7.70 (d, J = Hz, 1H), 7.49 (s, 1H), 6.87 (d, J = Hz, 1H), 
6.40 (s, 1H), 6.05 (s, 2H), 5.93 (s, 1H), 5.04 (s, 2H), 3.80 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 165.66, 165.24, 151.79, 147.76, 135.36, 127.33, 125.51, 
123.80, 109.53, 108.01, 101.84, 62.73, 52.05 
Anal. Calcd for C13H12O6 (264.23): C 59.09, H 4.58 Found: C 58.97. H 4.62 
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2-(methoxycarbonyl)allyl 1-naphthoate 
1
H NMR (500MHz, CDCl3): δ 8.94 (d, J = 8.5 Hz, 1H), 8.22 (d, J = 7.0 Hz, 1H), 8.02 
(d, J = 7.5 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.55-7.48 (m, 2H), 
6.46 (s, 1H), 6.00 (s, 1H), 5.17 (s, 2H), 3.83 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 166.73, 165.69, 135.32, 133.81, 133.59, 131.37, 130.31, 
128.54, 127.84, 127.77, 126.65, 126.24, 125.69, 124.46, 63.00, 52.06  
Anal. Calcd for C16H14O4 (270.28): C 71.10, H 5.22 Found: C 70.44, H 5.22 
 
 
2-(methoxycarbonyl)allyl anthracene-9-carboxylate 
1
H NMR (500MHz, CDCl3): δ 8.55 (s, 1H), 8.08-8.03 (m, 4H), 7.56-7.49 (m, 4H), 6.48 
(s, 1H), 6.03 (s, 1H), 5.36 (s, 2H), 3.85 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 164.31, 160.93, 130.27, 126.21, 124.88, 124.23, 123.90, 
123.83, 122.58, 122.32, 120.75, 120.23, 59.06, 47.44 
Anal. Calcd for C20H16O4 (320.34): C 74.99, H 5.03 Found: C 74.71, H 5.10 
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bis(2-(methoxycarbonyl)allyl) pyridine-2,6-dicarboxylate 
1
H NMR (500MHz, CDCl3): δ 8.30 (d, J = 8.0 Hz, 2H), 8.04 (t, J = 8.0 Hz, 1H), 6.46 (s, 
2H), 6.06 (s, 2H), 5.16 (s, 4H), 3.82 (s, 6H) 
13
C NMR (125MHz, CDCl3): δ 165.50, 163.90, 148.22, 138.29, 134.68, 128.09, 127.89, 
63.66, 52.10 
HRMS (ESI) m/z: calc’d for C17H17O8 [M+H]
+
 : 364.0988, found 364.1065 
 
 
 
bis(2-(methoxycarbonyl)allyl) terephthalate 
1
H NMR (500MHz, CDCl3): δ 8.12 (s, 4H), 6.44 (s, 2H), 5.96 (s, 2H), 5.09 (s, 4H), 3.81 
(s, 6H) 
13
C NMR (125MHz, CDCl3): δ 165.58, 165.11, 135.02, 133.85, 129.71, 127.98, 63.30, 
52.14 
HRMS (ESI) m/z: calc’d for C18H18O8 [M+H]
+
 : 363.1035, found 363.1115 
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tris(2-(methoxycarbonyl)allyl) benzene-1,3,5-tricarboxylate 
1
H NMR (500MHz, CDCl3): δ 8.88 (s, 3H), 6.46 (s, 3H), 5.97 (s, 3H), 5.12 (s, 6H), 3.82 
(s, 9H) 
13
C NMR (125MHz, CDCl3): δ 165.50, 164.24, 134.90, 134.82, 131.13, 128.27, 63.59, 
52.18 
Anal. Calcd for C24H24O12 (504.44): C 57.14, H 4.80 Found: C 57.41, H 4.84 
 
 
 
2-(methoxycarbonyl)allyl cinnamate 
1
H NMR (500MHz, CDCl3): δ 7.73 (d, J = 16Hz, 1H), 7.54-7.52 (m, 2H), 7.39-7.38 (m, 
3H), 6.48 (d, J = 16Hz, 1H), 6.40 (s, 1H), 5.91 (s, 1H), 4.96 (s, 2H), 3.80 (s, 3H) 
13
C NMR (125MHz, CDCl3): δ 166.27, 165.69, 145.43, 135.32, 134.25, 130.44, 128.91, 
128.14, 127.51, 117.52, 62.45, 52.04 
HRMS (ESI) m/z: calc’d for C12H11NO [M+Na]
+
 : 269.2518, found 269.0784 
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2-(methoxycarbonyl)allyl 4-(4-(bis(2-chloroethyl)amino)phenyl)butanoate 
1
H NMR (500MHz, CDCl3): δ 7.00 (d, J = 8Hz, 2H), 6.56 (d, J = 8Hz, 2H), 6.30 (s, 
1H), 5.77 (s, 1H), 4.74 (s, 2H), 3.72 (s, 3H), 3.65-3.62 (m, 4H), 3.57-3.54 (m, 4H), 2.50 
(t, J = 7.5Hz, 2H), 2.30 (t, J = 7Hz, 2H), 1.86 (quintet, J = 7.5Hz 2H) 
13
C NMR (125MHz, CDCl3): δ 172.90, 165.66, 144.37, 135.32, 130.45, 129.69, 127.55, 
112.18, 62.31, 53.59, 52.04, 40.53, 33.93, 33.49, 26.69 
Anal. Calcd for C19H25Cl2NO4 (402.31): C 56.72, H 6.26, N 3.48 Found: C 56.64, H 
6.22, N 3.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
References (Introduction) 
1. American Cancer Society. Cancer Facts and Figures. Am. Cancer Soc. (2017). 
doi:10.1101/gad.1593107 
2. Weinmann, H. Cancer Immunotherapy: Selected Targets and Small-Molecule 
Modulators. ChemMedChem 11, 450–466 (2016). 
3. Tong, X. P. et al. Key autophagic targets and relevant small-molecule compounds 
in cancer therapy. Cell Prolif. 48, 7–16 (2015). 
4. Zhao, Y., Aguilar, A., Bernard, D. & Wang, S. Small-molecule inhibitors of the 
MDM2 − p53 protein − protein interaction (MDM2 inhibitors ) in clinical trials for 
cancer treatment. J. Med. Chem. 58, 1038–1052 (2015). 
5. Maschinot, C. a, Pace, J. R. & Hadden, M. K. Synthetic Small Molecule Inhibitors 
of Hh Signaling As Anti-Cancer Chemotherapeutics. Curr. Med. Chem. 22, 4033–
57 (2015). 
6. Monroig, P. D. C., Chen, L., Zhang, S. & Calin, G. a. Small molecule compounds 
targeting miRNAs for cancer therapy. Adv. Drug Deliv. Rev. 81, 104–116 (2015). 
7. Belmar, J. & Fesik, S. W. Small molecule Mcl-1 inhibitors for the treatment of 
cancer. Pharmacol. Ther. 145, 76–84 (2014). 
8. Bai, L., Smith, D. C. & Wang, S. Small-molecule SMAC mimetics as new cancer 
therapeutics. Pharmacol. Ther. 144, 82–95 (2014). 
9. Su, Y. et al. Small molecule with big role: MicroRNAs in cancer metastatic 
microenvironments. Cancer Lett. 344, 147–156 (2014). 
10. Van de Donk, N. W. C. J. et al. Monoclonal antibodies targeting CD38 in 
hematological malignancies and beyond. Immunol. Rev. 270, 95–112 (2016). 
11. Henricks, L. M., Schellens, J. H. M., Huitema, A. D. R. & Beijnen, J. H. The use 
of combinations of monoclonal antibodies in clinical oncology. Cancer Treat. Rev. 
41, 859–867 (2015). 
12. Moussavou, G., Ko, K., Lee, J.-H. & Choo, Y.-K. Production of monoclonal 
antibodies in plants for cancer immunotherapy. Biomed Res. Int. 2015, 306164 
(2015). 
13. Li, G., Wang, S., Xue, X., Qu, X. & Liu, H. Monoclonal antibody-related drugs for 
cancer therapy. Drug Discov. Ther. 7, 178–184 (2013). 
74 
 
14. Melssen, M. & Slingluff, C. L. Vaccines targeting helper T cells for cancer 
immunotherapy. Curr. Opin. Immunol. 47, 85–92 (2017). 
15. Holay, N., Kim, Y., Lee, P. & Gujar, S. Sharpening the Edge for Precision Cancer 
Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines. Front. 
Immunol. 8, 800 (2017). 
16. Lichtenegger, F. S., Krupka, C., Haubner, S., Köhnke, T. & Subklewe, M. Recent 
developments in immunotherapy of acute myeloid leukemia. J. Hematol. Oncol. 
10, 142 (2017). 
17. Grierson, P., Lim, K.-H. & Amin, M. Immunotherapy in gastrointestinal cancers. 
J. Gastrointest. Oncol. 8, 474–484 (2017). 
18. Kumai, T., Fan, A., Harabuchi, Y. & Celis, E. Cancer immunotherapy: moving 
forward with peptide T cell vaccines. Curr. Opin. Immunol. 47, 57–63 (2017). 
19. Gao, X. et al. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer 
Immunotherapy. Front. Immunol. 8, 774 (2017). 
20. Yang, K. Inhibitors of the PD-1 / PD-L1 axis for the treatment of head and neck 
cancer : current status and future perspectives. 2007–2014 (2017). 
doi:10.2147/DDDT.S140687 
21. Wu, L. & de Perrot, M. Radio-immunotherapy and chemo-immunotherapy as a 
novel treatment paradigm in malignant pleural mesothelioma. Transl. Lung Cancer 
Res. 6, 325–334 (2017). 
22. Dozier, J., Zheng, H. & Adusumilli, P. S. Immunotherapy for malignant pleural 
mesothelioma: current status and future directions. Transl. Lung Cancer Res. 6, 
315–324 (2017). 
23. Hamid, O., Hoffner, B., Gasal, E., Hong, J. & Carvajal, R. D. Oncolytic 
immunotherapy: unlocking the potential of viruses to help target cancer. Cancer 
Immunol. Immunother. (2017). doi:10.1007/s00262-017-2025-8 
24. Parp, T. & Cancer, P. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and 
Promise. 1–7 (2016). 
25. Puigvert, J. C., Sanjiv, K. & Helleday, T. Targeting DNA repair, DNA metabolism 
and replication stress as anti-cancer strategies. FEBS J. 283, 232–245 (2016). 
26. O’Connor, M. J. Targeting the DNA Damage Response in Cancer. Mol. Cell 60, 
547–560 (2015). 
75 
 
27. Erdmann, A., Halby, L., Fahy, J. & Arimondo, P. B. Targeting DNA Methylation 
with Small Molecules: What ’ s Next? (2014). doi:10.1021/jm500843d 
28. Ali, A. & Bhattacharya, S. DNA binders in clinical trials and chemotherapy. 
Bioorganic Med. Chem. 22, 4506–4521 (2014). 
29. Hosoya, N. & Miyagawa, K. Targeting DNA damage response in cancer therapy. 
Cancer Sci. 105, 370–388 (2014). 
30. Furgason, J. M. & Bahassi, E. M. Targeting DNA repair mechanisms in cancer. 
Pharmacol. Ther. 137, 298–308 (2013). 
31. Zhang, D., Wang, H. B., Brinkman, K. L., Han, S. X. & Xu, B. Strategies for 
targeting the DNA damage response for cancer therapeutics. Chin J Cancer 31, 
359–363 (2012). 
32. Hurley, L. H. DNA and its associated processes as targets for cancer therapy. Nat. 
Rev. Cancer 2, 188–200 (2002). 
33. Povirk, L. F. & Shuker, D. E. DNA damage and mutagenesis induced by nitrogen 
mustards. Mutat. Res. Genet. Toxicol. 318, 205–226 (1994). 
34. Musser, S. M., Pan, S. S., Egorin, M. J., Kyle, D. J. & Callery, P. S. Alkylation of 
Dna With Aziridine Produced During the Hydrolysis of N,N’,N''-
Triethylenethiophosphoramide. Chem. Res. Toxicol. 5, 95–99 (1992). 
35. Gates, K. S., Nooner, T. & Dutta, S. N7-Alkylguanine Residues in DNA. 17, 
(2004). 
36. Nejad, M. I., Johnson, K. M., Price, N. E. & Gates, K. S. A New Cross-Link for an 
Old Cross-Linking Drug: The Nitrogen Mustard Anticancer Agent 
Mechlorethamine Generates Cross-Links Derived from Abasic Sites in Addition to 
the Expected Drug-Bridged Cross-Links. Biochemistry 55, 7033–7041 (2016). 
37. Agarwal, S., Jangir, D. K., Mehrotra, R., Lohani, N. & Rajeswari, M. R. A 
structural insight into major groove directed binding of nitrosourea derivative 
nimustine with DNA: A spectroscopic study. PLoS One 9, 2–9 (2014). 
38. Drabløs, F. et al. Alkylation damage in DNA and RNA - Repair mechanisms and 
medical significance. DNA Repair (Amst). 3, 1389–1407 (2004). 
39. Boose, R. B. 2-Clioroethanol Formation as Evidence for a 2-Chloroethyl 
Alkylating Intermediate during Chemical Degradation of. 35, 568–576 (1975). 
40. Hartley, J. a., O’Hare, C. C. & Baumgart, J. DNA alkylation and interstrand cross-
linking by treosulfan. Br. J. Cancer 79, 264–266 (1999). 
76 
 
41. Iwamoto, T. et al. DNA intrastrand cross-link at the 5′-GA-3′ sequence formed by 
busulfan and its role in the cytotoxic effect. Cancer Sci. 95, 454–458 (2004). 
42. Streeper, R. T., Cotter, R. J., Colvin, M. E., Hilton, J. & Michael Colvin, O. 
Molecular Pharmacology of Hepsulfam, NSC 3296801: Identification of Alkylated 
Nucleosides, Alkylation Site, and Site of DNA Cross-Linking. Cancer Res. 55, 
1491–1498 (1995). 
43. Ponti, M., Souhami, R. L., Fox, B. W. & Hartley, J. a. DNA interstrand 
crosslinking and sequence selectivity of dimethanesulphonates. Br. J. Cancer 63, 
743–7 (1991). 
44. Shaloam, D. & Tchounwou, P. B. Cisplatin in cancer therapy: Molecular 
mechanisms of action. Eur. J. Pharmacol. 740, 364–378 (2014). 
45. Gescher, A. & Threadgill, M. D. The Metabolism of Triazene Antitumor Drugs. 
Pharmacol. Ther. 32, 191–205 (1987). 
46. Marchesi, F. et al. Triazene compounds: Mechanism of action and related DNA 
repair systems. Pharmacol. Res. 56, 275–287 (2007). 
47. Xu, Y. & Her, C. Inhibition of topoisomerase (DNA) I (TOP1): DNA damage 
repair and anticancer therapy. Biomolecules 5, 1652–1670 (2015). 
48. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. 
Cancer 6, 789–802 (2006). 
49. Chandra Bharadwaj, K. Intramolecular Morita–Baylis–Hillman and Rauhut–
Currier reactions. A catalytic and atom economic route for carbocycles and 
heterocycles. RSC Adv. 5, 75923–75946 (2015). 
50. Wei, Y. & Shi, M. Recent advances in organocatalytic asymmetric Morita-Baylis-
Hillman/aza-Morita-Baylis-Hillman Reactions. Am. Chem. Soc. 2, 42–53 (2012). 
51. Ma, G.-N., Jiang, J.-J., Shi, M. & Wei, Y. Recent extensions of the Morita-Baylis-
Hillman reaction. Chem. Commun. (Camb). 5496–5514 (2009). 
doi:10.1039/b909405a 
52. Basavaiah, D., Venkateswara Rao, K. & Jannapu Reddy, R. The Baylis–Hillman 
reaction: a novel source of attraction, opportunities, and challenges in synthetic 
chemistry. Chem. Soc. Rev. 36, 1581 (2007). 
53. Basavaiah, D. & Roy, S. Derivatives Using the Baylis # Hillman Bromides 
Dimethyl Sulfide Induced [ 3 + 2 ] Annulation Strategy : An Efficient Synthesis of 
Functionalized Dihydropyrazole Derivatives Using the Baylis - Hillman Bromides. 
2–5 (2008). doi:10.1021/ol800424v 
77 
 
54. Basavaiah, D. & Veeraraghavaiah, G. The Baylis–Hillman reaction: a novel 
concept for creativity in chemistry. Chem. Soc. Rev. 41, 68–78 (2012). 
55. Basavaiah, D., Badsara, S. S. & Sahu, B. C. Baylis-Hillman Bromides as a Source 
of 1,3-Dipoles: Sterically Directed Synthesis of Oxindole-Fused Spirooxirane and 
Spirodihydrofuran Frameworks. Chem. - A Eur. J. 19, 2961–2965 (2013). 
56. Basavaiah, D., Reddy, B. S. & Badsara, S. S. Recent contributions from the 
Baylis-Hillman reaction to organic chemistry. Chem. Rev. 110, 5447–5674 (2010). 
57. Basavaiah, D., Reddy, K. R. & Kumaragurubaran, N. An expedient, facile and 
simple one-pot synthesis of 2-methylenealkanoates and alkanenitriles from the 
Baylis-Hillman bromides in aqueous media. Nat. Protoc. 2, 2665–76 (2007). 
58. Basavaiah, D., Sharada, D. S. & Kumaragurubaran, N. The Baylis - Hillman 
Reaction : One-Pot Facile Synthesis of 2 , 4-Functionalized 1 , 4-Pentadienes The 
Baylis - Hillman reaction is a three-component reaction involving the construction 
of the carbon - carbon bond between the R -position of activated alke. 7135–7137 
(2002). 
59. Frlan, R., Sova, M., Gobec, S., Stavber, G. & Asar, Z. Cobalt-Catalyzed Cross-
Coupling of Grignards with Allylic and Vinylic Bromides: Use of Sarcosine as a 
Natural Ligand. J. Org. Chem. 80, 7803–7809 (2015). 
60. Bai, X., Lv, L. & Li, Z. Copper-catalyzed tandem trifluoromethylation–cyclization 
of olefinic carbonyls: synthesis of trifluoromethylated 2,3-dihydrofurans and 3,4-
dihydropyrans. Org. Chem. Front. 3, 804–808 (2016). 
61. Sova, M., Frlan, R., Gobec, S., Stavber, G. & Asar, Z. D-Glucosamine in iron-
catalysed cross-coupling reactions of Grignards with allylic and vinylic bromides: 
Application to the synthesis of a key sitagliptin precursor. Appl. Organomet. 
Chem. 29, 528–535 (2015). 
62. Zhu, Z. et al. Discovery of Novel Hydroxamates as Highly Potent Tumor Necrosis 
Factor-α Converting Enzyme Inhibitors: Part I-Discovery of Two Binding Modes. 
J. Med. Chem. 51, 725–736 (2008). 
63. Enz, A. et al. Gamma-lactams—A novel scaffold for highly potent and selective 
α7 nicotinic acetylcholine receptor agonists. Bioorg. Med. Chem. Lett. 19, 1287–
1291 (2009). 
64. Grim, J. C., Garber, K. C. a & Kiessling, L. L. Glycomimetic building blocks: A 
divergent synthesis of epimers of shikimic acid. Org. Lett. 13, 3790–3793 (2011). 
65. Casey, T. C. et al. Stereoselective α, α'-annelation reactions of 1,3-dioxan-5-ones. 
J. Org. Chem. 75, 7461–7464 (2010). 
78 
 
66. Maezaki, N., Sawamoto, H., Suzuki, T., Yoshigami, R. & Tanaka, T. Highly 
stereoselective synthesis of functionalized β,β-di- and trisubstituted vinylic 
sulfoxides by cu-catalyzed conjugate addition of organozinc reagents. J. Org. 
Chem. 69, 8387–8393 (2004). 
67. Teng, H. L., Huang, H. & Wang, C. J. Catalytic asymmetric construction of 
spiro(γ-butyrolactam-γ- butyrolactone) moieties through sequential reactions of 
cyclic imino esters with Morita-Baylis-Hillman bromides. Chem. - A Eur. J. 18, 
12614–12618 (2012). 
68. Singh, D. et al. Natural Product Inspired Designing and Synthesis of β-Carboline 
and γ-Lactones Based Molecular Hybrids. Org. Biomol. Chem. 8154–8166 (2016). 
doi:10.1039/C6OB01216G 
69. Hanessian, S. & Margarita, R. 1,3-Asymmetric induction in dianionic allylation 
reactions of amino acid derivatives-synthesis of functionally useful enantiopure 
glutamates, pipecolates and pyroglutamates. Tetrahedron Lett. 39, 5887–5890 
(1998). 
70. Jia, ., Williams, R. A Diastereoselective Intramolecular Pauson-Khand Approach 
to the Construction of the BC Ring System in Tuberostemoninol. Tetrahedron 
Asymmetry 19, 2901–2906 (2008). 
71. Alanine, T. A., Galloway, W. R. J. D., McGuire, T. M. & Spring, D. R. Concise 
synthesis of substituted quinolizin-4-ones by ring-closing metathesis. European J. 
Org. Chem. 2014, 5767–5776 (2014). 
72. Xuan, J., Daniliuc, C. G. & Studer, A. Construction of Polycyclic γ-Lactams and 
Related Heterocycles via Electron Catalysis. Org. Lett. 18, 6372–6375 (2016). 
73. Luo, Z. & Naguib, M. A synthetic approach for (S)-(3-benzyl-3-methyl-2,3-
dihydro-benzofuran-6-yl)-piperidin-1-yl-methanone, a selective CB2 receptor 
agonist. Tetrahedron Lett. 53, 3316–3318 (2012). 
74. Kłossowski, S., Muchowicz, A., Firczuk, M., Marta, S. & Redzej, A. Studies 
toward Novel Peptidomimetic Inhibitors of Thioredoxin − Thioredoxin Reductase 
System. 97–99 (2012). 
75. Singh, V., Pathak, R. & Batra, S. Significant yield improvement in the 
stereoselective synthesis of allyl cyanides from Baylis-Hillman derivatives in 
aqueous medium under the influence of the phase-transfer catalyst. Catal. 
Commun. 8, 2048–2052 (2007). 
76. Gowrisankar, S., Kim, K. H., Kim, S. H. & Kim, J. N. Synthesis of 1,5-dicarbonyl 
and related compounds from Baylis-Hillman adducts via Pd-mediated 
decarboxylative protonation protocol. Tetrahedron Lett. 49, 6241–6244 (2008). 
79 
 
77. Pandey, G., Kant, R. & Batra, S. A general route to the synthesis of indoloazocines 
using allyl bromides prepared from Morita-Baylis-Hillman adducts. Tetrahedron 
Lett. 56, 930–933 (2015). 
78. Bakthadoss, M. . B. & Vinayagam, V. . A novel protocol for the facile 
construction of tetrahydroquinoline fused tricyclic frameworks via an 
intramolecular 1,3-dipolar nitrile oxide cycloaddition reaction. Org. Biomol. 
Chem. 13, 10007–10014 (2015). 
79. Sankar, R. K., Kumbhare, R. S., Dharmaraja, A. T. & Chakrapani, H. A 
phenacrylate scaffold for tunable thiol activation and release. Chem. Commun. 
(Camb). 50, 15323–6 (2014). 
80. Rajan, Y. C., Kanakam, C. C., Selvam, S. P. & Murugesan, K. A study on the 
synthesis and biological and optical properties of methylene-dinaphthyl bis-
chromanones: the utility of Baylis-Hillman adducts. Tetrahedron Lett. 48, 8562–
8565 (2007). 
81. Ferreira, M. et al. Allylic isothiouronium salts: The discovery of a novel class of 
thiourea analogues with antitumor activity. Eur. J. Med. Chem. 129, 151–158 
(2017). 
82. Silveira, G. P. et al. Allylic thiocyanates as a new class of antitubercular agents. 
Bioorganic Med. Chem. Lett. 22, 6486–6489 (2012).  
 
 
 
 
 
 
 
 
 
 
 
80 
 
References (Results and Discussion) 
1. Frlan, R., Sova, M., Gobec, S., Stavber, G. & Asar, Z. Cobalt-Catalyzed Cross-Coupling 
of Grignards with Allylic and Vinylic Bromides: Use of Sarcosine as a Natural Ligand. J. 
Org. Chem. 80, 7803–7809 (2015). 
2. Bai, X., Lv, L. & Li, Z. Copper-catalyzed tandem trifluoromethylation–cyclization of 
olefinic carbonyls: synthesis of trifluoromethylated 2,3-dihydrofurans and 3,4-
dihydropyrans. Org. Chem. Front. 3, 804–808 (2016). 
3. Sova, M., Frlan, R., Gobec, S., Stavber, G. & Asar, Z. D-Glucosamine in iron-catalysed 
cross-coupling reactions of Grignards with allylic and vinylic bromides: Application to the 
synthesis of a key sitagliptin precursor. Appl. Organomet. Chem. 29, 528–535 (2015). 
4. Zhu, Z. et al. Discovery of Novel Hydroxamates as Highly Potent Tumor Necrosis Factor-
α Converting Enzyme Inhibitors: Part I-Discovery of Two Binding Modes. J. Med. Chem. 
51, 725–736 (2008). 
5. Enz, A. et al. Gamma-lactams—A novel scaffold for highly potent and selective α7 
nicotinic acetylcholine receptor agonists. Bioorg. Med. Chem. Lett. 19, 1287–1291 (2009). 
6. Grim, J. C., Garber, K. C. a & Kiessling, L. L. Glycomimetic building blocks: A divergent 
synthesis of epimers of shikimic acid. Org. Lett. 13, 3790–3793 (2011). 
7. Casey, T. C. et al. Stereoselective-annelation reactions of 1,3-dioxan-5-ones. J. Org. 
Chem. 75, 7461–7464 (2010). 
8. Maezaki, N., Sawamoto, H., Suzuki, T., Yoshigami, R. & Tanaka, T. Highly 
stereoselective synthesis of functionalized β,β-di- and trisubstituted vinylic sulfoxides by 
cu-catalyzed conjugate addition of organozinc reagents. J. Org. Chem. 69, 8387–8393 
(2004). 
9. Teng, H. L., Huang, H. & Wang, C. J. Catalytic asymmetric construction of spiro(γ-
butyrolactam-γ- butyrolactone) moieties through sequential reactions of cyclic imino 
esters with Morita-Baylis-Hillman bromides. Chem. - A Eur. J. 18, 12614–12618 (2012). 
10. Singh, D. et al. Natural Product Inspired Designing and Synthesis of β-Carboline and γ-
Lactones Based Molecular Hybrids. Org. Biomol. Chem. 8154–8166 (2016). 
doi:10.1039/C6OB01216G 
11. Hanessian, S. & Margarita, R. 1,3-Asymmetric induction in dianionic allylation reactions 
of amino acid derivatives-synthesis of functionally useful enantiopure glutamates, 
pipecolates and pyroglutamates. Tetrahedron Lett. 39, 5887–5890 (1998). 
12. Jia, ., Williams, R. A Diastereoselective Intramolecular Pauson-Khand Approach to the 
Construction of the BC Ring System in Tuberostemoninol. Tetrahedron Asymmetry 19, 
2901–2906 (2008). 
81 
 
13. Alanine, T. A., Galloway, W. R. J. D., McGuire, T. M. & Spring, D. R. Concise synthesis 
of substituted quinolizin-4-ones by ring-closing metathesis. European J. Org. Chem. 2014, 
5767–5776 (2014). 
14. Xuan, J., Daniliuc, C. G. & Studer, A. Construction of Polycyclic γ-Lactams and Related 
Heterocycles via Electron Catalysis. Org. Lett. 18, 6372–6375 (2016). 
15. Luo, Z. & Naguib, M. A synthetic approach for (S)-(3-benzyl-3-methyl-2,3-dihydro-
benzofuran-6-yl)-piperidin-1-yl-methanone, a selective CB2 receptor agonist. Tetrahedron 
Lett. 53, 3316–3318 (2012). 
16. Kłossowski, S., Muchowicz, A., Firczuk, M., Marta, S. & Redzej, A. Studies toward 
Novel Peptidomimetic Inhibitors of Thioredoxin − Thioredoxin Reductase System. 97–99 
(2012). 
17. Singh, V., Pathak, R. & Batra, S. Significant yield improvement in the stereoselective 
synthesis of allyl cyanides from Baylis-Hillman derivatives in aqueous medium under the 
influence of the phase-transfer catalyst. Catal. Commun. 8, 2048–2052 (2007). 
18. Gowrisankar, S., Kim, K. H., Kim, S. H. & Kim, J. N. Synthesis of 1,5-dicarbonyl and 
related compounds from Baylis-Hillman adducts via Pd-mediated decarboxylative 
protonation protocol. Tetrahedron Lett. 49, 6241–6244 (2008). 
19. Pandey, G., Kant, R. & Batra, S. A general route to the synthesis of indoloazocines using 
allyl bromides prepared from Morita-Baylis-Hillman adducts. Tetrahedron Lett. 56, 930–
933 (2015). 
20. Bakthadoss, M. . B. & Vinayagam, V. . A novel protocol for the facile construction of 
tetrahydroquinoline fused tricyclic frameworks via an intramolecular 1,3-dipolar nitrile 
oxide cycloaddition reaction. Org. Biomol. Chem. 13, 10007–10014 (2015). 
21. Sankar, R. K., Kumbhare, R. S., Dharmaraja, A. T. & Chakrapani, H. A phenacrylate 
scaffold for tunable thiol activation and release. Chem. Commun. (Camb). 50, 15323–6 
(2014). 
22. Rajan, Y. C., Kanakam, C. C., Selvam, S. P. & Murugesan, K. A study on the synthesis 
and biological and optical properties of methylene-dinaphthyl bis-chromanones: the utility 
of Baylis-Hillman adducts. Tetrahedron Lett. 48, 8562–8565 (2007). 
23. Ferreira, M. et al. Allylic isothiouronium salts: The discovery of a novel class of thiourea 
analogues with antitumor activity. Eur. J. Med. Chem. 129, 151–158 (2017). 
24. Silveira, G. P. et al. Allylic thiocyanates as a new class of antitubercular agents. 
Bioorganic Med. Chem. Lett. 22, 6486–6489 (2012). 
25. J. Sravan Kumar, M. A. Alam, Shirisha Gurrapu, Grady Nelson, Michael Williams, M. A. 
C. & Joseph L. Johnson, Subash Jonnalagadda, and V. R. M. Synthesis and Biological 
Evaluation of Novel Benzoxaboroles as Potential Antimicrobial and Anticancer Agents. J. 
Heterocycl. Chem. 50, 814–820 (2012). 
82 
 
26. Tekkam, S., Alam, MA., Just, MJ., Berry, SM., Johnson, JL., Jonnalagadda, SC., and 
Mereddy, V. Stereoselective Synthesis of Pyroglutamate Natural Product Analogs from α-
Aminoacids and their Anti-Cancer Evaluation. Anticancer Agents Med Chem 13, 1514–
1530 (2013). 
27. Solano, L. N. et al. Synthesis, in vitro, and in vivo evaluation of novel functionalized 
quaternary ammonium curcuminoids as potential anti-cancer agents. Bioorganic Med. 
Chem. Lett. 25, 5777–5780 (2015). 
28. Goede V, Eichhorst B, Fischer K, Wendtner CM, H. M. Past, present and future role of 
chlorambucil in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 56, doi: 
10.3109/10428194.2014.963077 (2015). 
29. Lepretre S, Dartigeas C, Feugier P, Marty M, S. G. Systematic review of the recent 
evidence for the efficacy and safety of chlorambucil in the treatment of B-cell 
malignancies. Leuk Lymphoma 57, doi: 10.3109/10428194.2015 (2016). 
30. Hallek, M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, 
and treatment. Am. J. Hematol. 90, 446 – 60 (2015). 
31. Sourdeval M, Boisvieux-Ulrich E, Gendron MC, M. F. Mitochondrial Inside-Out 
Signalling During Alkylating Agent-Induced Anoikis. Front. Biosci. 14, 1917–1931 
(2009). 
32. Beranek, D. T. Distribution of methyl and ethyl adducts following alkylation with 
monofunctional alkylating agents. Mutat. Res. - Fundam. Mol. Mech. Mutagen. 231, 11–
30 (1990). 
33. Drabløs, F. et al. Alkylation damage in DNA and RNA - Repair mechanisms and medical 
significance. DNA Repair (Amst). 3, 1389–1407 (2004). 
34. Rasmussen, K., Peterson, B.L., Jacobo, E., Penick, G.D., Sall, J. Cytologic effects of 
thiotepa and adriamycin and normal canine urothelium. Acta Cytol. 3, 237–243 (1980). 
35. Kinoshita, J. et al. N-methyl-N-nitrosourea induced acute alteration of retinal function and 
morphology in monkeys. Investig. Ophthalmol. Vis. Sci. 56, 7146–7158 (2015). 
36. Rogakou, E. P., Pilch, D. R., Orr, a. H., Ivanova, V. S. & Bonner, W. M. Double-stranded 
Brekas Induce Histone H2AX phosphorylation on Serine 139. J. Biol. Chem. 273, 5858–
5868 (1998). 
37. Meador, J. a et al. Histone H2AX is a critical factor for cellular protection against DNA 
alkylating agents. Oncogene 27, 5662–71 (2008). 
38. Debiak, M., Kehe, K. & Bürkle, A. Role of poly(ADP-ribose) polymerase in sulfur 
mustard toxicity. Toxicology 263, 20–25 (2009). 
39. Baptiste-Okoh, N., Barsotti, A. M. & Prives, C. A role for caspase 2 and PIDD in the 
process of p53-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 105, 1937–42 (2008). 
83 
 
40. Yang, K., Hitomi, M. & Stacey, D. W. Variations in cyclin D1 levels through the cell 
cycle determine the proliferative fate of a cell. Cell Div. 1, 32 (2006). 
41. Daniell, H. F-box proteins FBXO31 and FBX4 in regulation of cyclin D1 degradation 
upon DNA damage. Pigment Cell Melanoma Res. 22, 518–519 (2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
Appendix 
85 
 
86 
 
 
87 
 
88 
 
89 
 
90 
 
 
91 
 
92 
 
 
93 
 
94 
 
95 
 
96 
 
 
97 
 
98 
 
 
99 
 
100 
 
 
101 
 
102 
 
 
103 
 
104 
 
 
105 
 
106 
 
 
107 
 
108 
 
 
109 
 
 
110 
 
111 
 
112 
 
 
113 
 
 
114 
 
 
115 
 
116 
 
 
117 
 
118 
 
119 
 
120 
 
 
121 
 
122 
 
 
 
 
 
